Pfizer Ltd.

“Pfizer India is a profitable but stagnant MNC marketing subsidiary with no reinvestment flywheel, structural DPCO pricing constraints, revenue growth chronically below the Indian pharma market, and governance that consistently subordinates minority shareholder interests to the US parent. At 25.7x trailing earnings, the market assigns quality-compounder multiples to a yield vehicle delivering 6-8% earnings growth at best. The primary risk is not operational deterioration but parent-driven value extraction via RPTs and potential involuntary delisting below intrinsic value. The 10-year total return outlook of 1.5-2x (~4-7% CAGR) is deeply inferior to Indian equity alternatives, offering no margin of safety and no catalyst for re-acceleration.”